Form 4 for ENSC Ensysce Biosciences, Inc.

Accepted 2023-02-01 00:00:00 ET · period of report 2022-12-09 · accession 0001493152-23-003343 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-02-01	2022-12-09	ENSC	GOWER BOB G	Dir	P - Purchase	$1.40	+357.1K	753.1K	+90%	+$500.0K
D	2023-02-01	2022-12-09	ENSC	GOWER BOB G	Dir	A - Grant	—	+714.3K	716.4K	+34,357%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-09	P	A	357,143	$1.40	753,095	D	—	—	(F1) On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock"). (F2) On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share.
2	Derivative	Warrants	2022-12-09	A	A	714,286	—	716,365	D	$1.40 · — to 2027-12-09	714,286 Common Stock	(F1) On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock"). (F3) On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance.